智飞生物CA111注射液临床试验获批

Core Viewpoint - Zhifei Biological (300122) announced that its subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1: Company Developments - The CA111 injection developed by Chen'an Biological is designed to reduce side effects compared to similar single-target drugs due to its dual agonist synergistic effect [1]